Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Impact of pre-adapted HIV transmission.

Carlson JM, Du VY, Pfeifer N, Bansal A, Tan VY, Power K, Brumme CJ, Kreimer A, DeZiel CE, Fusi N, Schaefer M, Brockman MA, Gilmour J, Price MA, Kilembe W, Haubrich R, John M, Mallal S, Shapiro R, Frater J, Harrigan PR, Ndung'u T, Allen S, Heckerman D, Sidney J, Allen TM, Goulder PJ, Brumme ZL, Hunter E, Goepfert PA.

Nat Med. 2016 Jun;22(6):606-13. doi: 10.1038/nm.4100. Epub 2016 May 16.

2.

HIV-1-Specific CD8 T Cells Exhibit Limited Cross-Reactivity during Acute Infection.

Du VY, Bansal A, Carlson J, Salazar-Gonzalez JF, Salazar MG, Ladell K, Gras S, Josephs TM, Heath SL, Price DA, Rossjohn J, Hunter E, Goepfert PA.

J Immunol. 2016 Apr 15;196(8):3276-86. doi: 10.4049/jimmunol.1502411. Epub 2016 Mar 16.

3.

HIV DNA Vaccine: Stepwise Improvements Make a Difference.

Felber BK, Valentin A, Rosati M, Bergamaschi C, Pavlakis GN.

Vaccines (Basel). 2014 May 14;2(2):354-79. doi: 10.3390/vaccines2020354. Review.

4.

DNA Immunization for HIV Vaccine Development.

Chen Y, Wang S, Lu S.

Vaccines (Basel). 2014 Feb 25;2(1):138-59. doi: 10.3390/vaccines2010138. Review.

5.

HLA Class-II Associated HIV Polymorphisms Predict Escape from CD4+ T Cell Responses.

Erdmann N, Du VY, Carlson J, Schaefer M, Jureka A, Sterrett S, Yue L, Dilernia D, Lakhi S, Tang J, Sidney J, Gilmour J, Allen S, Hunter E, Heath S, Bansal A, Goepfert PA.

PLoS Pathog. 2015 Aug 24;11(8):e1005111. doi: 10.1371/journal.ppat.1005111. eCollection 2015 Aug.

6.

Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.

Overton ET, Sterrett S, Westfall AO, Kahan SM, Burkholder G, Zajac AJ, Goepfert PA, Bansal A.

AIDS. 2014 Nov 13;28(17):2627-2631. doi: 10.1097/QAD.0000000000000475.

7.

The influence of delivery vectors on HIV vaccine efficacy.

Ondondo BO.

Front Microbiol. 2014 Aug 22;5:439. doi: 10.3389/fmicb.2014.00439. eCollection 2014. Review.

8.

Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine.

Buglione-Corbett R, Pouliot K, Marty-Roix R, Li W, West K, Wang S, Morelli AB, Lien E, Lu S.

Hum Vaccin Immunother. 2014;10(4):1078-90. Epub 2014 Feb 10.

9.

Non-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals.

Kløverpris HN, Jackson A, Handley A, Hayes P, Gilmour J, Riddell L, Chen F, Atkins M, Boffito M, Walker BD, Ackland J, Sullivan M, Goulder P.

PLoS One. 2013 Oct 4;8(10):e74389. doi: 10.1371/journal.pone.0074389. eCollection 2013.

10.

Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.

Buglione-Corbett R, Pouliot K, Marty-Roix R, West K, Wang S, Lien E, Lu S.

PLoS One. 2013 Sep 3;8(9):e74820. doi: 10.1371/journal.pone.0074820. eCollection 2013.

11.

Human immunodeficiency virus vaccine an update.

Beena V, Choudhary K, Rajeev R, Sivakumar R, Heera R, Padmakumar S.

J Oral Maxillofac Pathol. 2013 Jan;17(1):76-81. doi: 10.4103/0973-029X.110741.

12.

Functional deficits of pertussis-specific CD4+ T cells in infants compared to adults following DTaP vaccination.

Sharma SK, Pichichero ME.

Clin Exp Immunol. 2012 Sep;169(3):281-91. doi: 10.1111/j.1365-2249.2012.04613.x.

13.

Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.

Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, Hural J, Lubeck M, Eldridge J, Cardinali M, Blattner WA, Sobieszczyk M, Suriyanon V, Kalichman A, Weiner DB, Baden LR; NIAID HIV Vaccine Trials Network.

PLoS One. 2012;7(1):e29231. doi: 10.1371/journal.pone.0029231. Epub 2012 Jan 5.

14.

Bacterial magnetic particles as a novel and efficient gene vaccine delivery system.

Tang YS, Wang D, Zhou C, Ma W, Zhang YQ, Liu B, Zhang S.

Gene Ther. 2012 Dec;19(12):1187-95. doi: 10.1038/gt.2011.197. Epub 2011 Dec 15.

15.

Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.

Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, Defawe OD, Baden L, Goepfert P, Tomaras GD, Montefiori DC, McElrath MJ, Saavedra L, Lau CY, Graham BS; NIAID HIV Vaccine Trials Network.

PLoS One. 2011;6(9):e24517. doi: 10.1371/journal.pone.0024517. Epub 2011 Sep 12.

16.

Interleukin-2 production by polyfunctional HIV-1-specific CD8 T cells is associated with enhanced viral suppression.

Akinsiku OT, Bansal A, Sabbaj S, Heath SL, Goepfert PA.

J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):132-40. doi: 10.1097/QAI.0b013e318224d2e9.

17.

Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.

Sabbaj S, Pass RF, Goepfert PA, Pichon S.

J Infect Dis. 2011 Jun 1;203(11):1534-41. doi: 10.1093/infdis/jir138.

18.

Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.

Tran E, Nielsen JS, Wick DA, Ng AV, Johnson LD, Nesslinger NJ, McMurtrie E, Webb JR, Nelson BH.

PLoS One. 2010 Dec 22;5(12):e15625. doi: 10.1371/journal.pone.0015625.

19.

Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity.

Bot A, Qiu Z, Wong R, Obrocea M, Smith KA.

J Transl Med. 2010 Dec 14;8:132. doi: 10.1186/1479-5876-8-132.

20.

Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.

Patel V, Valentin A, Kulkarni V, Rosati M, Bergamaschi C, Jalah R, Alicea C, Minang JT, Trivett MT, Ohlen C, Zhao J, Robert-Guroff M, Khan AS, Draghia-Akli R, Felber BK, Pavlakis GN.

Vaccine. 2010 Jul 5;28(30):4827-36. doi: 10.1016/j.vaccine.2010.04.064. Epub 2010 May 6.

Supplemental Content

Support Center